Evidence map›Paper›PMID 27010220›Full record

ArticleJournal of medicinal chemistry2016

Affinity-Guided Design of Caveolin-1 Ligands for Deoligomerization.

Amanda J H Gilliam, Joshua N Smith, Dylan Flather, Kevin M Johnston, Andrew M Gansmiller, Dmitry A Fishman, Joshua M Edgar, Mark Balk, Sudipta Majumdar, Gregory A Weiss

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Small molecules targeting endocytic uptake and recycling pathways.Frontiers in cell and developmental biology · 2023
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Amanda J H GilliamDepartment of Chemistry, and ‡Department of Molecular Biology and Biochemistry, University of California , Irvine, California 92697-2025, United States.
Joshua N SmithDepartment of Chemistry, and ‡Department of Molecular Biology and Biochemistry, University of California , Irvine, California 92697-2025, United States.
Dylan FlatherDepartment of Chemistry, and ‡Department of Molecular Biology and Biochemistry, University of California , Irvine, California 92697-2025, United States.
Kevin M JohnstonDepartment of Chemistry, and ‡Department of Molecular Biology and Biochemistry, University of California , Irvine, California 92697-2025, United States.
Andrew M GansmillerDepartment of Chemistry, and ‡Department of Molecular Biology and Biochemistry, University of California , Irvine, California 92697-2025, United States.
Dmitry A FishmanDepartment of Chemistry, and ‡Department of Molecular Biology and Biochemistry, University of California , Irvine, California 92697-2025, United States.
Joshua M EdgarDepartment of Chemistry, and ‡Department of Molecular Biology and Biochemistry, University of California , Irvine, California 92697-2025, United States.
Mark BalkDepartment of Chemistry, and ‡Department of Molecular Biology and Biochemistry, University of California , Irvine, California 92697-2025, United States.
Sudipta MajumdarDepartment of Chemistry, and ‡Department of Molecular Biology and Biochemistry, University of California , Irvine, California 92697-2025, United States.
Gregory A WeissDepartment of Chemistry, and ‡Department of Molecular Biology and Biochemistry, University of California , Irvine, California 92697-2025, United States.

Funding

Engineering Soluble Aggregation-Prone and Membrane-Bound ProteinsR01GM078528 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI WEISS, GREGORY A. · 2006 to 2010
$1.3M
Membrane Protein Co- Crystallization with Highly Crystalline and Soluble ProteinsR01GM100700 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI WEISS, GREGORY A. · 2012 to 2015
$1.1M
NIGMS NIH HHS R01 GM078528NIGMS NIH HHS R01 GM100700
6 · The paper itself

Abstract

Caveolin-1 is a target for academic and pharmaceutical research due to its many cellular roles and associated diseases. We report peptide WL47 (1), a small, high-affinity, selective disrupter of caveolin-1 oligomers. Developed and optimized through screening and analysis of synthetic peptide libraries, ligand 1 has 7500-fold improved affinity compared to its T20 parent ligand and an 80% decrease in sequence length. Ligand 1 will permit targeted study of caveolin-1 function.

Indexed as

BiopolymersCaveolin 1LigandsBiopolymersCaveolin 1Ligands

Identifiers

PMID27010220
PMCPMC5529100

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.